Literature DB >> 7031858

Controlled comparison of nalidixic acid or lactulose with placebo in shigellosis.

H B Hansson, G Barkenius, S Cronberg, I Juhlin.   

Abstract

Nalidixic acid and lactulose, respectively, were compared with placebo in a controlled double-blind study in 43 patients with bacteriologically verified shigellosis. All the strains were susceptible to nalidixic acid. Treatment with nalidixic acid resulted in cure in 72%, which was a significantly better result than with placebo (cure in 21%).

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7031858     DOI： 10.3109/inf.1981.13.issue-3.06

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN： 0036-5548


  6 in total

1.  Increasing the intestinal resistance of rats to the invasive pathogen Salmonella enteritidis: additive effects of dietary lactulose and calcium.

Authors:  I M Bovee-Oudenhoven; D S Termont; P J Heidt; R Van der Meer
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

Review 2.  Antibiotic therapy for Shigella dysentery.

Authors:  Prince Rh Christopher; Kirubah V David; Sushil M John; Venkatesan Sankarapandian
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

3.  Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults.

Authors:  F Rogerie; D Ott; J Vandepitte; L Verbist; P Lemmens; I Habiyaremye
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

4.  Diminished efficacy of colonic adaptation to lactulose occurs in patients with inflammatory bowel disease in remission.

Authors:  Andrew Szilagyi; Julie Rivard; Ian Shrier
Journal:  Dig Dis Sci       Date:  2002-12       Impact factor: 3.199

Review 5.  Use of quinolones in the treatment of gastrointestinal infections.

Authors:  H L DuPont
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 6.  Quinolones and the gastrointestinal tract.

Authors:  B E Murray
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.